| Angela Dawn Howard, | |
|
308 W Maple Ave, Lancaster, KY 40444-1005 | |
| (859) 792-6844 | |
| Not Available |
| Full Name | Angela Dawn Howard |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 308 W Maple Ave, Lancaster, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730658337 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 002943 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Angela Dawn Howard, 115 Angela Way, Lancaster, KY 40444-9599 Ph: (859) 339-2138 | Angela Dawn Howard, 308 W Maple Ave, Lancaster, KY 40444-1005 Ph: (859) 792-6844 |
News Archive
The National Association of Healthcare Advocacy Consultants (NAHAC), the nation's first professional association for people working as healthcare and patient advocates, will hold its first annual conference November 14-15 at the University of California, Berkeley Clark Kerr Campus.
University of California, Irvine today announced the launch of its new Clinical Research Certificate Program. In order to close the widening gap between the rapid expansion of biomedical discoveries and the application of those discoveries in a clinical environment, UC Irvine School of Medicine developed the program in partnership with UC Irvine Extension to equip medical industry professionals with the academic knowledge, technical skill and critical thinking ability necessary to understand and evaluate clinical studies...
Severin Schwan thinks the skeptics are wrong. Those who shun the pharmaceutical sector for its lack of prospects don't understand the potential created by a rapidly growing understanding of genetics and molecular biology, and the new drugs that will follow. ... the chief executive of Roche Holding AG, the world's seventh-largest drug firm by sales, is an informed optimist.
AVEO Pharmaceuticals, Inc. today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Fla.
› Verified 9 days ago